2022
Foy SP, Jacoby K, Bota DA, Hunter T, Pan Z, Stawiski E, Ma Y, Lu W, Peng S, Wang CL, Yuen B, Dalmas O, Heeringa K, Sennino B, Conroy A, Bethune MT, Mende I, White W, Kukreja M, Gunturu S, Humphrey E, Hussaini A, An D, Litterman AJ, Quach BB, Ng AHC, Lu Y, Smith C, Campbell KM, Anaya D, Skrdlant L, Huang EY, Mendoza V, Mathur J, Dengler L, Purandare B, Moot R, Yi MC, Funke R, Sibley A, Stallings-Schmitt T, Oh DY, Chmielowski B, Abedi M, Yuan Y, Sosman JA, Lee SM, Schoenfeld AJ, Baltimore D, Heath JR, Franzusoff A, Ribas A, Rao AV, Mandl SJ. Non-viral precision T cell receptor replacement for personalized cell therapy. Nature. 2022 Nov 10:1–10. Epub ahead of print. PMID: 36356599; PMCID: PMC9768791. DOI: 10.1038/s41586-022-05531-1
Douglas C, Lomeli N, Bota DA. BSCI-03 THE ROLE OF LONP1 IN DRIVING ENHANCED PMT IN THE ‘LEADING EDGE’ NICHE IN GLIOBLASTOMA. Neurooncol Adv. 2022 Aug 5;4(Suppl 1):i1. PMCID: PMC9354152. DOI: 10.1093/noajnl/vdac078.003
Bota DA, Taylor TH, Lomeli N, Kong XT, Fu BD, Schönthal AH, Singer S, Blumenthal DT, Senecal FM, Linardou H, Rokas E, Antoniou DG, Schijns VEJC, Chen TC, Elliot J, Stathopoulos A. A Prospective, Cohort Study of SITOIGANAP to Treat Glioblastoma When Given in Combination With Granulocyte-Macrophage Colony-Stimulating Factor/Cyclophosphamide/Bevacizumab/Nivolumab or Granulocyte-Macrophage Colony-Stimulating Factor/Cyclophosphamide/Bevacizumab/Pembrolizumab in Patients Who Failed Prior Treatment With Surgical Resection, Radiation, and Temozolomide. Front Oncol. 2022 Jun 28;12:934638. PMID: 35837107; PMCID: PMC9273968. DOI: 10.3389/fonc.2022.934638
Gooch M, Mehta A, John T, Lomeli N, Naeem E, Mucci G, Toh YL, Chan A, Bota DA, Torno L. Feasibility of Cognitive Training to Promote Recovery in Cancer-Related Cognitive Impairment in Adolescent and Young Adult Patients. J Adolesc Young Adult Oncol. 2022 Jun;11(3):290-296. PMID: 34672806; PMCID: PMC9464087. DOI: 10.1089/jayao.2021.0055
2021
Douglas C, Bota DA, Di K, Das B, Lepe J. DDRE-50. INVESTIGATING THE ROLE OF LonP1 IN GLIOBLASTOMA TUMOR PROGRESSION. Neuro Oncol. 2021 Nov 12;23(Suppl 6):vi85. PMCID: PMC8598710. DOI: 10.1093/neuonc/noab196.334.
Lepe J, Douglas C, Lomeli N, Di K, Das B, & Bota DA. (2021). DDRE-31. MITOCHONDRIAL TRAFFICKING AS A TARGET FOR GBM THERAPY. Neuro-Oncology, 23(Supplement_6), vi81-vi81. DOI: 10.1093/neuonc/noab196.315 Retrieved from https://escholarship.org/uc/item/7n23539g
Lomeli N, Bota DA, Argueta D, Gupta K. NCMP-13. ID8 OVARIAN CANCER MOUSE MODEL MIMICS NEUROLOGICAL SEQUELAE OF OVARIAN CANCER IN WOMEN. Neuro-Oncology. 2021 Nov 12;23(Supplement_6):vi149-. DOI: 10.1093/neuonc/noab196.584
Hoerig CM, Plant-Fox AS, Pulley MD, Di K, Bota DA. Exploring the role and clinical implications of proteasome inhibition in medulloblastoma. Pediatr Blood Cancer. 2021 Oct;68(10):e29168. Epub 2021 Jun 11. PMID: 34114315. DOI: 10.1002/pbc.29168
Lomeli N, Lepe J, Gupta K, Bota DA. Cognitive complications of cancer and cancer-related treatments–Novel paradigms. Neuroscience Letters. 2021 Apr 1;749:135720. DOI: 10.1016/j.neulet.2021.135720
2020
Cloughesy TF, Petrecca K, Walbert T, Butowski N, Salacz M, Perry J, Damek D, Bota DA, Bettegowda C, Zhu JJ, Iwamoto F, Placantonakis D, Kim L, Elder B, Kaptain G, Cachia D, Moshel Y, Brem S, Piccioni D, Landolfi J, Chen CC, Gruber H, Rao AR, Hogan D, Accomando W, Ostertag D, Montellano TT, Kheoh T, Kabbinavar F, Vogelbaum MA. Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma: A Randomized Clinical Trial. JAMA Oncol. 2020 Dec 1;6(12):1939-1946. PMID: 33119048; PMCID: PMC7596685. DOI: 10.1001/jamaoncol.2020.3161.
Lomeli N, Di K, Pearre DC, Chung TF, Bota DA. Mitochondrial-associated impairments of temozolomide on neural stem/progenitor cells and hippocampal neurons. Mitochondrion. 2020 Feb 8;52:56-66. PMCID: PMC7415494. NIHMSID: 1569829. DOI: 10.1016/j.mito.2020.02.001.
Reardon DA, Desjardins A, Vredenburgh JJ, O’Rourke DM, Tran DD, Fink KL, Nabors LB, Li G, Bota DA, Lukas RV, Ashby LS, Duic JP, Mrugala MM, Cruickshank S, Vitale L, He Y, Green JA, Yellin MJ, Turner CD, Keler T, Davis TA, Sampson JH; ReACT trial investigators. Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial. Clin Cancer Res. 2020 Apr 1;26(7):1586-1594. doi: 10.1158/1078-0432.CCR-18-1140. Epub 2020 Feb 7. PMID: 32034072. DOI: 10.1158/1078-0432.CCR-18-1140
2019
Brown TJ, Bota DA, van Den Bent MJ, Brown PD, Maher E, Aregawi D, Liau LM, Buckner JC, Weller M, Berger MS, Glantz M. Management of low-grade glioma: a systematic review and meta-analysis. Neurooncol Pract. 2019 Jul;6(4):249-258. Epub 2018 Aug 18. PMID: 31386075; PMCID: PMC6660818. DOI: 10.1093/nop/npy034
Di K, Lomeli N, Bota DA, Das BC. Magmas inhibition as a potential treatment strategy in malignant glioma. Journal of neuro-oncology. 2019 Jan;141(2):267-76. DOI: 10.1007/s11060-018-03040-8
2018
Bota DA, Chung J, Dandekar M, Carrillo JA, Kong XT, Fu BD, Hsu FP, Schönthal AH, Hofman FM, Chen TC, Zidovetzki R, Pretto C, Strik A, Schijns VE, Stathopoulos A. Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4+ T-lymphocyte counts. CNS Oncol. 2018 Jul 1;7(3): CNS22. PMCID: PMC6200061.
Lomeli N, Bota DA. Targeting HSP90 in malignant gliomas: onalespib as a potential therapeutic. Transl Cancer Res. 2018 Apr;7(4):6215-6226. PMID: 31840022; PMCID: PMC6910236. DOI: 10.21037/tcr.2018.03.05
Pearre DC, Bota DA. Chemotherapy-related cognitive dysfunction and effects on quality of life in gynecologic cancer patients. Expert Rev Qual Life Cancer Care. 2018;3(1):19-26. Epub 2018 Feb 26. PMID: 30775449; PMCID: PMC6377208. DOI: 10.1080/23809000.2018.1443811
2017
John T, Lomeli N, Bota DA. Systemic cisplatin exposure during infancy and adolescence causes impaired cognitive function in adulthood. Behav Brain Res. 2017 Feb 15;319:200-206. Epub 2016 Nov 13. PMID: 27851909; PMCID: PMC5332150. DOI: 10.1016/j.bbr.2016.11.013
Lomeli N, Bota DA, Davies KJA. Diminished stress resistance and defective adaptive homeostasis in age-related diseases. Clin Sci (Lond). 2017 Oct 25;131(21):2573-2599. PMID: 29070521. DOI: 10.1042/CS20160982.
Lomeli N, Di K, Czerniawski J, Guzowski JF, Bota DA. Cisplatin-induced mitochondrial dysfunction is associated with impaired cognitive function in rats. Free Radic Biol Med. 2017 Jan;102:274-286. PMCID: PMC5308450.
2016
Di K, Lloyd GK, Abraham V, MacLaren A, Burrows FJ, Desjardins A, Trikha M, Bota DA. Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier. Neuro Oncol. 2016 Jun;18(6):840-8. PMCID: PMC4864261.
Di K, Lomeli N, Wood SD, Vanderwal CD, Bota DA. Mitochondrial Lon is over-expressed in high-grade gliomas, and mediates hypoxic adaptation: potential role of Lon as a therapeutic target in glioma. Oncotarget. 2016 Nov 22;7(47):77457-77467. PMCID: PMC5340227
Selected Other Publications
Schijns VE, Pretto C, Devillers L, Pierre D, Hofman FM, Chen TC, Mespouille P, Hantos P, Glorieux P, Bota DA, Stathopoulos A. First clinical results of a personalized immunotherapeutic vaccine against recurrent, incompletely resected, treatment-resistant glioblastoma multiforme (GBM) tumors, based on combined allo- and auto-immune tumor reactivity. Vaccine. 2015 May 28;33(23):2690-6. PMCID: N/A. DOI: 10.1016/j.vaccine.2015.03.095
Bota DA, Alexandru-Abrams D, Pretto C, Hofman FM, Chen TC, Fu B, Carrillo JA, Schijns VE, Stathopoulos A. Use of ERC-1671 Vaccine in a Patient with Recurrent Glioblastoma Multiforme after Progression during Bevacizumab Therapy: First Published Report. Perm J. 2015 Spring;19(2):41-6. PubMed Central PMCID: PMC4403580.
Andres AL, Gong X, Di K, Bota DA. Low-doses of cisplatin injure hippocampal synapses: a mechanism for ‘chemo’ brain?. Exp Neurol. 2014 May;255:137-44. PMCID: PMC4059602.
Di K, Keir ST, Alexandru-Abrams D, Gong X, Nguyen H, Friedman HS, Bota DA. Profiling Hsp90 differential expression and the molecular effects of the Hsp90 inhibitor IPI-504 in high-grade glioma models. J Neurooncol. 2014 Dec;120(3):473-81. PMCID: N/A. DOI: 10.1007/s11060-014-1579-y
Bota DA, Alexandru D, Keir ST, Bigner D, Vredenburgh J, Friedman HS. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells’ VEGF production and angiogenesis. J Neurosurg. 2013 Dec;119(6):1415-23. PMCID: PMC4550014.
Di K, Linskey ME, Bota DA. TRIM11 is overexpressed in high-grade gliomas and promotes proliferation, invasion, migration and glial tumor growth. Oncogene. 2013 Oct 17;32(42):5038-47. PMCID: PMC3766389.
Gong X, Schwartz PH, Linskey ME, Bota DA. Neural stem/progenitors and glioma stem-like cells have differential sensitivity to chemotherapy. Neurology. 2011 Mar 29;76(13):1126-34. PMCID: PMC3269770.
Ge L, Hoa N, Bota DA, Natividad J, Howat A, Jadus MR. Immunotherapy of brain cancers: the past, the present, and future directions. Clin Dev Immunol. 2010;2010:296453. PMCID: PMC3061456.
Bota DA, Ngo JK, Davies KJ. Downregulation of the human Lon protease impairs mitochondrial structure and function and causes cell death. Free Radic Biol Med. 2005 Mar 1;38(5):665-77. PMCID: N/A. DOI: 10.1016/j.freeradbiomed.2004.11.017
Bota DA, Davies KJ. Lon protease preferentially degrades oxidized mitochondrial aconitase by an ATP-stimulated mechanism. Nat Cell Biol. 2002 Sep;4(9):674-80. PMCID: N/A. DOI: 10.1038/ncb836.
Bota DA, Van Remmen H, Davies KJ. Modulation of Lon protease activity and aconitase turnover during aging and oxidative stress. FEBS Lett. 2002 Dec 4;532(1-2):103-6. PMCID: N/A. DOI: 10.1016/s0014-5793(02)03638-4